Clinical Outcomes of Upper Eyelid Blepharoplasty

Abstract

Objective: To observe effect of surgery on upper eyelid blepharoplasty in an Asian population.

Methods: This retrospective study was conducted at Armed Forces Institute of Ophthalmology from May 2023 to July 2023. This study included patients from 30 to 70 years of age. Patients with upper double eye lid (dermatochalasis) and xanthelasma were included in this study. Patients were counseled about the risk of surgery. Subcutaneous 0.5% lignocaine, approximately 0.6 ml was given after skin marking in each eye. Distance between eyelid margin and inferior margin eyebrow was marked 21mm, to avoid lagophthalmos. Wound approximation was done with 7-0 vicryl interrupted sutures. Follow up was done at day one and two weeks after upper lid blepharoplasty.

Results: After a follow up of 02 weeks of 35 subjects who underwent upper eyelid blepharoplasty, 24(68.4%) were females while 11(31.4%) were males. The mean average age + SD in years was 53.45± 1.06. All subjects underwent bilateral upper eyelid blepharoplasty in one sitting. Redo surgery was done in one (2.84%) subject after six months. Eyelid oedema was Grade-II on day one postoperatively and was absent after two weeks of follow up in all subjects. However, no lagophthalmos was seen in any of the subject.

Conclusion: Upper Eyelid blepharoplasty is the procedure of choice of correcting double eyelid and xanthelasma. It not only improves periorbital cosmesis but also plays an important part in improving patient vision and contrast.

doi: https://doi.org/10.12669/pjms.41.5.10950

How to cite this: Sameen M, Rebecca. Clinical Outcomes of Upper Eyelid Blepharoplasty. Pak J Med Sci. 2025;41(5):1318-1321.  doi: https://doi.org/10.12669/pjms.41.5.10950

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.